Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;14(9):507-517.
doi: 10.2217/epi-2021-0383. Epub 2022 Apr 27.

Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib

Francesca Salani  1   2   3 , Maryam Latarani  2 , Andrea Casadei-Gardini  4 , Priyadarsini Gangadharannambiar  2 , Lorenzo Fornaro  5 , Caterina Vivaldi  6 , Irene Pecora  7 , Valentina Massa  3 , Giorgia Marisi  8 , Matteo Canale  8 , Paola Ulivi  8 , Mario Scartozzi  9 , Mark Eccleston  10 , Gianluca Masi  6 , Francesco Crea  2
Affiliations
Free article

Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib

Francesca Salani et al. Epigenomics. 2022 May.
Free article

Abstract

Background: Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The authors tested the predictive power of circulating H3K27me3 and H3K36me3 in advanced hepatocellular carcinoma patients treated with sorafenib. Methods: A total of 80 plasma samples were tested for histone variants by ELISA. Changes from baseline to best response or progressive disease were correlated with patient survival. Results: A higher EZH2/SETD2 ratio predicted worse prognosis in this setting. H3K27me3 and H3K36me3 decreased from baseline to best response. The H3K27me3/H3K36me3 ratio increased from baseline to progressive disease. Higher ratios at best response were associated with shorter progression-free survival. Conclusion: The authors suggest that circulating H3K27me3/H3K36me3 ratio level acts as a predictive biomarker for sorafenib treatment outcomes in patients with advanced hepatocellular carcinoma.

Keywords: EZH2; H3K27me3; H3K27me3/H3K36me3 ratio; H3K36me3; HCC; SETD2; advanced disease; epigenetic biomarkers; sorafenib; treatment prediction.

Plain language summary

Hepatocellular carcinoma (HCC) is responsible for approximately 10% of all cancer-related deaths worldwide. It is caused mainly by dysmetabolic syndrome, which is the presence of multiple risk factors: abdominal obesity, high blood pressure, hypercholesterolemia and diabetes. The authors aimed to identify new and predictive factors for sorafenib treatment outcomes in advanced HCC patients. The authors enrolled 85 patients who received sorafenib at two Italian oncological institutions, testing their blood for the following epigenetic biomarkers: H3, H3.1 variant, H3K27me3 and H3K36me3. The authors found that H3K27me3 and H3K36me3 decreased from baseline to maximum tumor shrinkage, H3K27me3/H3K36me3 ratio increased from baseline to progressive disease and higher ratios were associated with shorter progression-free survival. The authors suggest that circulating H3K27me3/H3K36me3 ratio level acts as a predictive biomarker for sorafenib treatment outcomes in patients with advanced HCC, and its role warrants further investigation in different HCC therapeutic strategies.

PubMed Disclaimer

Publication types

LinkOut - more resources